Plant Name: Citrus limon
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ADORA2B; | |
| PTPN1; | |
| TDP1; HSD17B10; ALOX15; ALDH1A1; | |
| MAPK1; | |
| CA2; CA13; CA1; CA12; CA9; CA3; CA14; CA5B; CA5A; CA4; CA6; CA7; | |
| ESR1; ESR2; | |
| NR1H4; | |
| KDM4E; | |
| MMP9; MMP1; MMP2; | |
| CASP1; CASP7; | |
| HIF1A; NFKB1; | |
| RAB9A; NPC1; LMNA; MAPT; | |
| XDH; | |
| L3MBTL1; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Small molecule receptor (family A GPCR) | ADORA2B | Adenosine A2b receptor | P29275 | CHEMBL255 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
| Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.074E-11 | 2.127E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.182E-10 | 4.619E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.461E-10 | 8.793E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 8.519E-10 | 1.091E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.107E-09 | 2.415E-06 | ALOX15, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.040E-08 | 8.924E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.104E-08 | 3.082E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.828E-07 | 1.105E-04 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.753E-07 | 2.023E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0005496; steroid binding | 1.311E-06 | 5.285E-04 | CYP3A4, ESR1, ESR2, NPC1, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.229E-06 | 8.516E-04 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.238E-30 | 2.696E-26 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0034754; cellular hormone metabolic process | 4.046E-06 | 1.377E-03 | ALDH1A1, CYP1A1, CYP1B1, CYP3A4, ESR1 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 4.841E-06 | 1.622E-03 | ESR1, ESR2 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.019E-05 | 3.126E-03 | CA2, CA7, HIF1A, MAPK1, NPC1, NR1H4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 1.131E-05 | 3.421E-03 | CASP7, CYP1A1, CYP1B1, ESR1, MAPK1, NFKB1, NPC1 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.450E-05 | 4.182E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.450E-05 | 4.182E-03 | CYP1A1, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 1.760E-05 | 4.863E-03 | ADORA2B, ALOX15, CA2, CA9, CYP1B1, HIF1A, LMNA, MAPK1, MAPT, MMP9, NFKB1, PTPN1, TDP1 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.764E-05 | 4.863E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 2.440E-05 | 6.480E-03 | CA2, CA9, CASP1, CYP1A1, CYP1A2, ESR1, NFKB1, NPC1, NR1H4 |
| BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 2.896E-05 | 7.333E-03 | ADORA2B, CYP1B1, HIF1A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.896E-05 | 7.333E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.896E-05 | 7.333E-03 | ESR1, ESR2 |
| BP | GO:0008152; metabolic process | GO:0032963; collagen metabolic process | 3.127E-05 | 7.826E-03 | HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 3.282E-05 | 8.121E-03 | CASP1, CASP7, MAPT, XDH |
| BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 3.466E-05 | 8.391E-03 | CASP1, CYP1B1, ESR1, MAPK1, MMP2, MMP9, NFKB1, NR1H4, TSHR |
| BP | GO:0009987; cellular process | GO:0010647; positive regulation of cell communication | 3.919E-05 | 9.171E-03 | ADORA2B, ALOX15, CA2, CA7, CASP1, CYP1B1, HIF1A, MAPK1, MMP9, NFKB1, NR1H4, PTPN1, XDH |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 3.959E-05 | 9.171E-03 | HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0023052; signaling | GO:0023056; positive regulation of signaling | 4.097E-05 | 9.292E-03 | ADORA2B, ALOX15, CA2, CA7, CASP1, CYP1B1, HIF1A, MAPK1, MMP9, NFKB1, NR1H4, PTPN1, XDH |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 4.422E-05 | 9.928E-03 | CYP1A2, MAPK1, MMP9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 5.496E-23 | 3.989E-19 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.535E-22 | 4.898E-18 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.816E-15 | 4.943E-12 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, L3MBTL1, MMP1, MMP2, MMP9, NR1H4, PTPN1 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.106E-29 | 1.537E-27 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.129E-09 | 2.870E-07 | CYP2C9; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.130E-08 | 9.870E-07 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.713E-07 | 9.426E-06 | CYP2C9; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.870E-07 | 1.354E-05 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.226E-06 | 4.419E-05 | MMP2; MAPK1; ESR1; MMP9; ESR2 |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.770E-06 | 4.100E-05 | MMP1; MMP2; MAPK1; MMP9 |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.713E-05 | 2.381E-04 | MAPK1; ESR1; NFKB1; ESR2 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.446E-05 | 2.234E-04 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 7.221E-06 | 1.255E-04 | CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 7.214E-05 | 7.714E-04 | MMP2; MAPK1; HIF1A; ESR1; MMP9 |
| hsa05133 | Pertussis_Homo sapiens_hsa05133 | 2.015E-05 | 2.546E-04 | CASP7; CASP1; MAPK1; NFKB1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.930E-04 | 1.578E-03 | MMP1; MMP2; MAPK1; HIF1A; MMP9; NFKB1 |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 9.061E-05 | 8.397E-04 | CASP7; MAPK1; MMP9; NFKB1 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 9.718E-05 | 8.442E-04 | CYP2C9; ALOX15; MAPK1; CYP2C19 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 2.296E-04 | 1.680E-03 | CASP7; LMNA; MAPK1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.652E-05 | 8.397E-04 | CYP1A2; CYP1A1; CYP1B1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.246E-04 | 1.680E-03 | CASP7; CASP1; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 4.592E-04 | 2.888E-03 | CASP7; MAPK1; MAPT; HSD17B10 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.084E-03 | 5.935E-03 | CYP2C9; CYP1A2; ALOX15; ALDH1A1; CYP1A1; CYP2C19; CYP3A4; HSD17B10; XDH |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.205E-04 | 2.121E-03 | CYP2C9; ALOX15; CYP2C19 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 2.498E-04 | 1.736E-03 | CASP1; MAPK1; NFKB1 |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.332E-03 | 6.858E-03 | MMP2; MAPK1; NFKB1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.778E-04 | 2.888E-03 | CA2; NR1H4; CYP3A4 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 8.366E-04 | 4.846E-03 | CASP1; MAPK1; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.410E-03 | 6.997E-03 | MAPK1; HIF1A; NFKB1 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 2.080E-03 | 9.971E-03 | MAPK1; ESR1; HIF1A |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.730E-03 | 1.703E-02 | CYP1B1; MAPK1; MMP9; NFKB1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 3.798E-03 | 1.703E-02 | MAPK1; MMP9; NFKB1 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 6.287E-03 | 2.570E-02 | CASP1; MAPK1; NFKB1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 8.939E-03 | 3.024E-02 | MAPK1; NFKB1; TSHR |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 6.686E-03 | 2.655E-02 | MAPK1; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 7.385E-03 | 2.851E-02 | MAPK1; HIF1A |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 1.737E-02 | 4.928E-02 | MAPK1; MAPT; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 8.877E-03 | 3.024E-02 | MAPK1; NFKB1 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 5.181E-03 | 2.182E-02 | CYP1A1; CYP1B1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 1.077E-02 | 3.328E-02 | MAPK1; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 8.877E-03 | 3.024E-02 | MAPK1; HIF1A |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.571E-02 | 4.646E-02 | MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.638E-02 | 4.744E-02 | MMP2; MAPK1 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.077E-02 | 3.328E-02 | MAPK1; NFKB1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 9.137E-03 | 3.024E-02 | MAPK1; HIF1A |
| hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.077E-02 | 3.328E-02 | MAPK1; NFKB1 |
| hsa04623 | Cytosolic DNA-sensing pathway_Homo sapiens_hsa04623 | 8.366E-03 | 3.024E-02 | CASP1; NFKB1 |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 8.619E-03 | 3.024E-02 | MAPK1; NFKB1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 4.401E-03 | 1.912E-02 | CYP3A4; XDH |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.106E-02 | 3.341E-02 | PTPN1; MAPK1 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.110E-03 | 5.935E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 4.497E-05 | 5.209E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Herpes simplex virus infection | B00 | ADORA2B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2 |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; MAPK1; CA1; CA9; MMP9; ESR1; ESR1; NFKB1; MMP2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA2B |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; CASP1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Apnea | R06.81 | ADORA2B |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1 |
| I00-I99: Diseases of the circulatory system | Paroxysmal supraventricular tachycardia | I47-I49, I47.1, I47.2, R00.0 | ADORA2B |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | CASP1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; MAPK1; CA9; MMP9; MMP2 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | MMP9 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ADORA2B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; MMP2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MMP2 |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | RAB9A |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | CASP1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2 |